PDCD1 and colorectal carcinoma: Recently, an investigation proved that some human malignancies, such as CRC with impaired MMR, but not patients with complete chromosomal mismatch repair, respond to anti-PDCD1 therapy better, probably through the metabolic pathway of glycerol phospholipids (202).